Board Members

Dr. Jeffrey Newcorn received his medical degree from the University of Rochester in New York. He completed his general psychiatry and child and adolescent psychiatry training at Tufts-New England Medical Center, Boston. Dr. Newcorn is currently associate professor of psychiatry and pediatrics, as well as director, Division of ADHD and Learning Disorders at Icahn School of Medicine at Mount Sinai, and Director of Pediatric Psychopharmacology for the Mount Sinai Health System. Dr. Newcorn is a highly regarded clinician - researcher with special expertise in the areas of ADHD, aggression, descriptive psychopathology of child and adolescent disorders, and child and adolescent psychopharmacology, whose academic work spans both clinical and translational topics. He has been a member of the steering committee of the NIMH-funded multicenter study “Multimodal Treatment of Children with ADHD (MTA).” He was the primary investigator on an NIMH-funded ADHD Research Infrastructure Network devoted to understanding the neurobiology of ADHD, and has been (and currently is) the principal investigator or co-investigator on several NIMH-funded and industry-funded grants that examine the clinical presentation and neurobiological basis of ADHD and its treatment. An internationally recognized educator and an editorial board member of several leading child psychiatry and psychology journals, Dr. Newcorn directs an active clinical trials program, and has studied many of the newer medication treatments for ADHD. He has published over 250 peer-reviewed articles and book chapters on these and related subjects. Dr. Newcorn’s most recent research focuses on the clinical and neurobiological basis of differential response to ADHD treatments, utilizing data obtained from clinical, neuropsychological, pharmacogenetic and fMRI measures.

Dr. Childress received her medical degree from the Medical University of South Carolina where she also completed her psychiatry residency and child and adolescent fellowship training. She is board certified in both adult and child and adolescent psychiatry. Dr. Childress is currently in private practice in Las Vegas, Nevada and her focus is on clinical research with children and adults who have Attention-Deficit/Hyperactivity Disorder. She is an adjunct faculty member at the University of Nevada, Reno School of Medicine and Touro University Nevada. Dr. Childress has been a co-principal investigator on more than 130 industry sponsored clinical trials and is currently a sub-recipient for a grant from the Food and Drug Administration researching the relationship between pharmacokinetic and pharmacodynamic effects of different methylphenidate formulations in children who have ADHD. Dr. Childress has also been a coauthor on several peer-reviewed ADHD publications.

Dr. Biederman is Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, and Professor of Psychiatry at the Harvard Medical School. Dr. Biederman is Board Certified in General and Child Psychiatry.

He has been the recipient of the American Psychiatric Association Blanche Ittelson Award for Excellence in Child Psychiatric Research, the American Academy of Child and Adolescent Psychiatry Charlotte Norbert Rieger Award for Scientific Achievement. He has been inducted into the CHADD “Hall of Fame”. Dr Biederman has also been selected every year since its inception into the “The Best Doctors in America” compilation of the best physicians in the country.
Dr. Biederman has been a mentor to more than 15 junior investigators in the field. He is on the editorial board of multiple journals, a reviewer for most of the Psychiatric journals, and has served as a grant reviewer in the Child Psychopathology and Treatment Review Committee of the NIMH. Dr. Biederman is the author and co-author of close to 600 scientific articles, 650 scientific abstracts, and 70 book chapters.

In 2000, Dr. Biederman pioneered and established a Stanley Foundation Center at the Massachusetts General Hospital dedicated to the treatment of pediatric bipolar disorder. Dr. Biederman was the recipient of the 1998 NAMI Exemplary Psychiatrist award. He was also the recipient of the 2002 NARSAD Senior Investigator award. Since 2002 Dr. Biederman has been Associate Editor and from 2005-2006 Deputy Editor for Child Psychiatry in Biological Psychiatry, ranked as the third most impactful scientific journal in Psychiatry. In 2005 Dr. Biederman was appointed Chair of the section on ADHD at the World Psychiatric Association. He was also recently selected by the Massachusetts Psychiatric Society Awards committee as the recipient of the 2007 Outstanding Psychiatrist Award for Research. In 2007, Dr. Biederman received the Excellence in Research Award from the New England Council of Child and Adolescent Psychiatry. He was also awarded the Mentorship Award from the Department of Psychiatry at the Massachusetts General Hospital in September.

As of March 2007, Dr. Biederman has been ranked as the second highest producer of high-impact papers in psychiatry overall throughout the world with 235 papers cited a total of 7048 times over the past 10 years as determined by the Institute for Scientific Information (ISI). The same organization ranked Dr. Biederman at #1 in terms of total citations to his papers published on ADD/ADHD in the past decade. Dr. Biederman's work is supported by multiple federal and pharmaceutical industry grants.

Tanya Froehlich, MD, MS is a developmental-behavioral pediatrician whose research focuses on attention-deficit/hyperactivity disorder (ADHD) and related disorders. Her publications have investigated the prevalence of ADHD, ADHD medication use, and preschool psychotropic medication use. She also studies the contribution of environmental exposures (e.g., lead, tobacco, and pesticides) to ADHD etiology, and has served as co-investigator on a National Institute of Environmental Health Sciences R01 grant examining the effects of pyrethroid pesticide exposure on ADHD symptoms. In addition, Dr. Froehlich is working to identify predictors of ADHD medication response, and received a National Institute of Mental Health (NIMH) K23 Award to investigate this topic. Currently, she is the Principal Investigator on an NIMH-funded R01 aimed at characterizing effects of abrupt methylphenidate discontinuation, including evaluating genetic and phenotypic moderators of effect.

Dr. Froehlich also enhances care for children with ADHD through teaching and other professional activities. She has served as an invited speaker providing seminars for professionals and workshops for families in international, national, and regional forums. Currently, she serves on the Executive Board for the American Professional Society of ADHD and Related Disorders, co-chairs the Society for Developmental and Behavioral Pediatrics ADHD Special Interest Group, and is an Editorial Board Member for the Journal of Developmental and Behavioral Pediatrics. In addition, Dr. Froehlich has a strong interest in interprofessional training and mentoring. She is site Principal Investigator for a state-funded grant whose mission is train professionals from a variety of disciplines to provide enhanced care for families on Ohio Medicaid, with a special emphasis on care of developmental and mental health conditions. Dr. Froehlich is also supervisor for a Leadership Education in Neurodevelopmental Disorders interdisciplinary trainee group whose project focuses on elucidating the needs of families in homeless shelters. In addition, Dr. Froehlich serves as Associate Director of the Developmental and Behavioral Pediatrics Fellowship as well as the Director of Research Training for the Cincinnati Children’s Hospital Division of Developmental and Behavioral Pediatrics, where she is Associate Professor of Pediatrics.

Dr. Froehlich is a graduate of Yale University School of Medicine. She completed her residency in pediatrics at the Children’s Hospital of Philadelphia, as well as a Developmental-Behavioral Pediatrics and a National Research Service Award fellowship at Cincinnati Children’s Hospital Medical Center.

Dr. Seymour is an Assistant Professor with a dual appointment at the Johns Hopkins University School of Medicine within the Division of Child and Adolescent Psychiatry and at the Johns Hopkins Bloomberg School of Public Health within the Department of Mental Health. Dr. Seymour is a licensed clinical psychologist and clinical researcher who studies the neurobehavioral correlates of emotion dysregulation underlying child psychopathology especially Attention-Deficit/Hyperactivity Disorder (ADHD). Broadly, Dr. Seymour’s research focused on elucidating the neurobiological mechanisms underlying emotion dysregulation, especially poor frustration tolerance and irritability, in individuals with ADHD. Dr. Seymour’s research utilizes affective neuroscience techniques including: computerized behavioral tasks, physiological measurement and multimodal neuroimaging to better understand emotion regulation deficits in individuals with ADHD. Throughout her career, Dr. Seymour has also been involved in treatment outcome research involving individuals with ADHD. Most recently, she has been a Co-Investigator on an NIMH funded grant examining reward responsiveness as a mechanisms underlying successful treatment of college students with ADHD who engage in problematic alcohol use. Additionally, she is a collaborator on a grant examining the efficacy of a novel mindful movement based intervention for children with ADHD. Dr. Seymour’s research has been funded by the National Institutes of Mental Health, the Brain and Behavior Foundation and CHADD. Dr. Seymour serves on the editorial board for the Journal of Attention Disorders, and is a grant reviewer for the National Institute of Child Health and Human Development (NICHD). As a clinician, Dr. Seymour conducts comprehensive diagnostic evaluations and neuropsychological testing with individuals with ADHD and other comorbidities.

Dr. Seymour received her undergraduate degree in Psychology at the University of Notre Dame, and her doctorate in Clinical Psychology at the University of Maryland, College Park. She completed her pre-doctoral internship at Children’s National Medical Center in Washington, DC, and completed a two-year National Institutes of Mental Health T32 postdoctoral fellowship in Child Mental Health at Brown University Alpert Warren School of Medicine.

Maria Teresa Acosta, MD is a Board-Certified Pediatric Neurologist. She is currently the Principal Investigator of the ADHD Genetic Study at NHGRI/NIH. She has worked in the genetics of ADHD for more than 20 years, focusing on using very detailed phenotypes to identify genetic markers that confer susceptibility for ADHD in specific populations. In addition, as a Pediatric Neurologist and Behavioral Neurologist, she has worked for more than 25 years in clinical care and clinical research in developmental disabilities and behavioral problems, from neurotypical children to children with genetic conditions like Neurofibromatosis type 1 and rare diseases. Her extensive clinical research in Neurofibromatosis type 1 has been fundamental in the describing the cognitive and behavioral phenotypes in this population. In terms of translational research, her main interest has been in the identification of biomarkers to measure cognitive or behavioral changes associated with pharmacological and non-pharmacological interventions designed to treat cognitive deficits in a broad spectrum of genetic conditions. In addition, works with the Undiagnosed Disease Program at NIH/NHGRI program.

Lenard A. Adler, MD is the Director of the Adult ADHD Program in the Department of Psychiatry, Professor of Psychiatry and Child and Adolescent Psychiatry, and Vice Chair for Continuing Medical Education (CME) for Department of Psychiatry at the NYU School of Medicine. He obtained a BA in Economics from the College of Arts and Sciences at Cornell University in 1978. He earned his MD from Emory University School of Medicine in 1982, and completed his residency in Psychiatry in 1986 at NYU School of Medicine. He has been interviewed numerous times in national media venues, including 60 Minutes and the Today Show, as well as The New York Times, USA Today and U.S. News & World Report on Adult ADHD. He is an active investigator and frequent lecturer, who has authored and coauthored more than 130 peer-reviewed articles and book chapters. He is also author of the popular book on Adult ADHD: SCATTERED MINDS, G.P. Putnam’s Sons 2006 and co-editor of the textbook Attention-Deficit Hyperactivity Disorder in Children and Adults, Cambridge University Press 2015.

Kevin Antshel, PhD, is Professor of Psychology, Director of the Clinical Psychology doctoral program and Director of the ADHD Lifespan, Treatment Education and Research (ALTER) program at Syracuse University. He is also an Adjunct Associate Professor of Psychiatry at SUNY-Upstate Medical University in Syracuse, NY. Dr. Antshel is an active researcher and clinician and has specialized in ADHD for nearly 20 years. He has had the pleasure of training hundreds of doctoral students, residents in psychiatry, pediatrics and family medicine who have rotated through the ALTER clinic.

His research interests focus on understanding the heterogeneity of ADHD, especially ADHD in the context of medical disorders such as 22q11.2 deletion syndrome and phenylketonuria. Clinically, Dr. Antshel has focused on developing and testing innovative psychosocial treatments for adolescents and young adults with ADHD and associated conditions. More recently, Dr. Antshel has focused on issues related to college students with ADHD including how best to reduce stimulant misuse on college campuses.

Dr. Antshel has over 125 peer-reviewed publications, including papers in JAMA Psychiatry, Journal of the American Academy of Child and Adolescent Psychiatry, Journal of Child Psychology and Psychiatry, Psychological Medicine, Journal of Clinical Child & Adolescent Psychology and the American Journal of Psychiatry. He is on the editorial boards of the Journal of Attention Disorders, the ADHD Report and the Journal of Abnormal Child Psychology. In 2014, he co-edited an issue of Child and Adolescent Psychiatric Clinics of North America with Stephen Faraone, Ph.D. Dr. Antshel has served previously on the Scientific Program Committees for APSARD and the World Congress on ADHD. He regularly serves as a grant reviewer on NIH and international review committees.

Dr. Antshel is interested in joining the APSARD Board of Directors to both give back to APSARD as well as participate in strategic planning for the future.

Dr. Arnett’s research focuses on identifying subtypes of children with attention deficit hyperactivity disorder (ADHD) with the ultimate goal of achieving more personalized intervention approaches. Currently she is utilizing electrophysiology frequency (EEG) and event related potential (ERP) metrics to test competing latent profile models of homogenous, neurophysiologically-defined subtypes of ADHD in school age and young children. By combining EEG, ERP, and behavioral measures to establish homogenous subgroups, the results of these studies will directly inform future research on putative genetic and environmental factors associated with ADHD, and ultimately, development of precision medicine treatment for the disorder.

Lawrence W. Brown, MD is Associate Professor of Neurology and Pediatrics at the Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine of the University of Pennsylvania. Dr. Brown is past president of the Child Neurology Foundation and currently serves as chairman of its medical transition initiative to develop tools for successful transition. He is senior author on its consensus statement recently published in Neurology with endorsements by the American Academy of Neurology (AAN), American Academy of Pediatrics (AAP), the American Epilepsy Society (AES) and Child Neurology Society (CNS). He is co-principal investigator of an epilepsy education and transition project funded by the Health Resources Services Administration (HRSA) in collaboration with the AAP.

Dr. Brown is director of the Pediatric Neuropsychiatry Program, a multidisciplinary clinic for children with complex ADHD, Tourette syndrome, high functioning autism, and genetic disorders. He has been a principal investigator funded by the National Institutes of Mental Health in an international consortium to develop a data bank of well characterized individuals with Tourette syndrome and parents analyzed with whole exome sequencing. In addition, he is a senior clinician in the Sleep Center and Pediatric Regional Epilepsy Program where he has been principal investigator on numerous investigational drug trials.

He is an active member of CNS, AES and AAP (where he served two terms as Chairman of the Section of Neurology) and AAN. He served on the AAP Subcommittee on ADHD which revised guidelines for diagnosis and treatment of ADHD. In addition to peer reviewed research, Dr. Brown’s publications include associate editorship of Schwartz’s Clinical Handbook of Pediatrics, Fifth Edition, as well as all previous editions. He is a member of the editorial board of Pediatric Neurology. Locally, he served for many years as chairman of the Professional Advisory Board and on the executive board of the Epilepsy Foundation of Eastern Pennsylvania. Dr. Brown currently serves on the advisory committee for the Coordinating Center for Children and Youth with Epilepsy for the American Academy of Pediatrics with funding by HRSA and the Maternal Child Health Bureau as well as the data safety committee for the National Institute of Health’s Best Pharmaceutical for Children Act.

Almost 25 years ago he began a collaboration with the future APSARD president Tony Rostain to scientifically and comprehensively address the needs of children with neuropsychiatric problems. Since then, together and individually, they have worked tirelessly with this population. He is convinced that neurologists are crucial members of any effort to address developmental behavioral, emotional and cognitive brain disorders. They are the natural partners of pediatricians and psychiatrists as well as all who support the potential of all children with ADHD and related conditions. He wants to bring the voice of child neurology to APSARD and to promote the importance of APSARD to all child neurologists.

Dr. Thomas E. Brown is a clinical psychologist who earned his Ph.D. at Yale University. He is Director of the Brown Clinic for Attention and Related Disorders in Manhattan Beach, California. After 20 years of serving on the clinical faculty of Yale Medical School, he has now joined the clinical faculty of the Dept. of Psychiatry & Behavioral Sciences at the Keck Medical School of the University of Southern California as a clinical associate professor. In May, 2017 he relocated his clinic from CT to Manhattan Beach, CA. Dr. Brown is author of Smart but Stuck: Emotions in Teens and Adults with ADHD (Jossey-Bass/Wiley, 2014), A New Understanding of ADHD in Children & Adults: Executive Function Impairments (Routledge, 2013) and the prize-winning Attention Deficit Disorder: The Unfocused Mind in Children and Adults.(Yale Press, 2005). He edited ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults (American Psychiatric Press, 2009) and is author of the Brown ADD Scales (Pearson). His most recent book is Outside the Box: Rethinking ADD/ADHD in Children and Adults--A Practical Guide (American Psychiatric Publishing, 2017). He has presented symposia and workshops throughout the US and in more than 40 other countries. His website is: www.BrownADHDclinic.com

Dr. Busch is an internationally known Developmental-Behavioral Pediatrician, and Associate Clinical Professor of Pediatrics at Tufts University School of Medicine. She has over 30 years of leadership experience at the forefront of advancements in addressing neurodevelopmental disorders, child mental health and the prevention of child maltreatment.

A well-known specialist in the diagnosis and treatment of children, adolescents and young adults with ADHD and related learning and behavioral disorders, Dr. Busch is in demand as a thought leader, clinical expert, dynamic teacher and consultant. She served for 10 years on the Tufts Medical Center Institutional Review Board. She is an experienced clinical researcher and author of numerous scientific publications and online commentaries. Dr. Busch is on the Editorial Board of the Journal of Attention Disorders, and is an invited peer reviewer for a dozen other scientific journals. She has served on Clinical Advisory Boards and/or Speakers Bureaus for Akili Interactive, Alcobra, Ltd., Cephalon, Eli Lilly, Forest Laboratories, Ortho-McNeil-Janssen, Next Wave, NLS Pharma, Pfizer, Rhodes Pharmaceuticals, Shire/Takeda Pharmaceuticals, Shionogi, Sunovion Pharmaceuticals, Supernus Pharmaceuticals and Tris Pharmaceuticals. She also is a certified examiner for Major-Minor League Baseball and the National Football League.

Dr. Busch has been an active member of APSARD since its inception, and served as the Secretary of the Board of Directors from 2010-2018. She has served on the Executive Committee, was the Co-Chair of the Program Committee, Chair of the Nominating Committee, and she currently serves on APSARD's Education Steering Committee.

In addition to her work for APSARD, Dr. Busch serves as a Trustee of Tufts University and is on the Board of Advisors for the Jonathan M. Tisch College of Civic Life at Tufts University. She also is a gubernatorial appointee to the Board of Directors of the Massachusetts Children’s Trust, a private-public partnership dedicated to preventing child maltreatment. Her work in this area was recently recognized by the American Academy of Pediatrics and the National Alliance of Children’s Trust and Prevention Funds when she was honored with the 2015 Ray E. Helfer, M.D. Award. She currently also serves as a grant reviewer for the Cummings Foundation, Inc.

Sam Goldstein, Ph.D. is an Adjust Assistant Professor at the university of Utah School of Medicine and on staff at the University Neuropsychiatric Institute. He is Clinical Director of the Neurology Learning and Behavior Center. The Center conducts evaluation, consultation and provides treatment services to 300 individuals and families each year. Dr. Goldstein has authored fifty trade and science texts as well as over three dozen science based book chapters and thirty peer reviewed research articles. He has also co-authored six psychological tests. He currently serves as Editor in Chief of the Journal of Attention Disorders and sits on the editorial boards of six peer reviewed journals. He is Co-editor of the Encyclopedia of Child Development. Recent books include the Handbook of Intelligence: Evolutionary Theory, Historical Perspective and Current Concepts, Handbook of Resilience - 2nd Edition, Raising Resilient Children with Autism Spectrum Disorders, Handbooks of Neurodevelopmental and Genetic Disorders in Children and Adults, Assessment of Intelligence and Achievement, Assessment of Autism Spectrum Disorders, Handbook of Executive Functioning, Assessment of Impairment and Managing Children's Classroom Behavior: Creating Sustainable Resilient Classrooms. He is the co-author of the Autism Spectrum Rating Scales, Comprehensive Executive Functioning Inventory, Rating Scales of Impairment and the Cognitive Assessment System Second Edition. Currently, he has three books and four psychological tests in development. He has lecture to thousands of professionals and the lay public in the U.S., South America, Asia, Australia, and Europe.

David W. Goodman, M.D. is Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. He is also Director of the Adult Attention Deficit Disorder Center of Maryland in Lutherville and Director of Suburban Psychiatric Associates, LLC. A 1983 graduate of Albany Medical College of Union University, Dr. Goodman completed a medical/psychiatric internship at Baltimore City Hospital and his psychiatric residency at The Johns Hopkins Hospital in 1986. Dr. Goodman has continued a full time clinical practice focusing on the diagnosis and treatment of mood disorders, adult Attention Deficit/Hyperactivity Disorder, Anxiety Disorders. For over twenty-five years, he has been teaching psychiatric residents at The Johns Hopkins Hospital. Dr. Goodman has presented over 600 lectures to primary care physicians, psychiatrists, medical specialists and the general public. His psychiatric commentary has been featured on national (ABC World News, CNN Anderson Cooper 360, ESPN Sports Center) and regional television around the country, PBS and national affiliate stations, national magazines (U.S. News and World Report, Wall Street Journal, New York Times, USA Weekend Magazine, Boston Globe, BusinessWeek) and radio interviews around the country. Dr. Goodman has been a Principal Investigator for multi-site Phase II and III drug trials for the treatment of adult Attention Deficit/Hyperactivity Disorder and Major Depression. Dr. Goodman is the lead author on the largest adult ADHD trial published and the lead author on the largest survey assessment of physician clinical practice for adults with ADHD. He has published articles in peer-reviewed journals, authored four book chapters and The Black Book of ADHD. He serves as a prepublication peer reviewer for several national and international psychiatric journals. He continues to treat patients in a full time clinical practice.

Dr. Heiligenstein is board certified in Pediatrics, Child and Adolescent Psychiatry and General Psychiatry. He served in the US Army as Chief of Pediatrics at Ft. Sheridan Army Health Center. Following his psychiatry residency, he pursued a career in academic psychiatry before joining Eli Lilly as a Clinical Research Physician in the Neuroscience Division. In the latter role, he was the lead physician for a number of innovative study designs and was a strong advocate for the study of pharmaceuticals in children and adolescents. He is the inventor of atomoxetine for its use in ADHD and was the lead physician for the pediatric studies with fluoxetine. Following his career at Lilly, Dr. Heiligenstein has continued to consult to the pharmaceutical industry on the development of novel medications for ADHD. He has served as an expert on behalf of special needs youth whose parents are divorcing. He also served as a consultant psychiatrist in the British Columbia Provincial ADHD Program.

Beth Krone, PhD, is an early career Clinical Psychologist, who is fully licensed in New York State and has spent more than a decade working in the field of developmental disabilities and severe and persistent mental illness, specializing in ADHD and related disorders. She has risen through the ranks at the Icahn School of Medicine’s Department of Psychiatry, starting as a pre-doctoral intern in the Division of Child Psychiatry, and completing her post-doctoral studies in the Division of ADHD, Learning Disabilities, and Related Disorders. She currently works in the ADHD Clinical and Translational Trials Program at Icahn School of Medicine at Mount Sinai as a research coordinator and study clinician. Beth is an invited lecturer in medical school didactics, and for the APA accredited Psychologist training program at Mount Sinai’s Adolescent Health Center, where she trains clinicians in diagnostics and clinical management of ADHD. She is an adjunct Assistant Professor of Psychology at the City University of New York, and has a burgeoning career as an author and editor. A former New York City school teacher, Beth has extensive experience working with diverse populations in terms of age, race, religion, ethnicity, sexual orientation, economic standing, cognitive and intellectual talent, and ability/disability.

Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University.  For the past 20 years, she has been the Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital and for the past 14 years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship.  Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic.  She is Medical Director of the Providers’ Clinical Support System- Medication Assisted Treatments (PCSS-MAT), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director of a SAMHSA-supported State Targeted Response technical assistance grant to states that received funding to address the national opioid epidemic.

She is the principal investigator on several federally funded grants, including a U54 Medications Development grant evaluating novel treatments for opiate and cannabis use disorders, a K24 Mid-Career Investigator Award and collaborates on several other grants. Her current research interests include pharmacologic and psychotherapeutic treatment interventions for cocaine and marijuana use disorder, and treatment approaches for adults with substance use disorders and attention-deficit hyperactivity disorder along with other psychiatric illnesses.  Dr. Levin has over 200 articles and book chapters on a wide range of topics including treatments of substance use disorders, assessment and treatment of co-occurring psychiatric illnesses and vulnerabilities associated with substance use disorders.  She has served on several advisory panels and ad-hoc federal grant review groups and was as a member of the NIDA – Initial Review Group:  Training and Career Development Subcommittee for 8 years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry and past Chair of the APA Council on Addiction Psychiatry.

Gregory W. Mattingly, MD is an Associate Clinical Professor and Psychopharmacology Course Master in the Department of Psychiatry at the Washington University School of Medicine in St Louis, Missouri.
Dr. Mattingly graduated Summa Cum Laude in chemical engineering before pursuing his medical degree at Washington University where he received a Fullbright Scholarship. He then completed his psychiatry residency at Washington University and is a diplomate of the American Board of Psychiatry and Neurology. He is board certified in psychiatry with a subspecialty in adolescent psychiatry. Dr. Mattingly has received numerous awards and distinctions including the Academy of Child and Adolescent Psychiatry National Leadership Award, the Upjohn Neuropsychiatry Research Award, and the Southern Psychiatric Association
Research Award.
As a principal investigator in over 300 clinical trials, he has been an invited presenter at numerous national and international medical conferences. Having served as a certified examiner for both the NFL and MLB, Dr. Mattingly also sits on the board of directors for Headway House; a “club house” program for individuals with developmental disabilities and chronic mental health conditions in St Louis. Dr. Mattingly’s work has been published in The Journal of Neuropsychiatry and Clinical Neurosciences, The Journal of Clinical Psychiatry, The Journal of Child and Adolescent Psychiatry, Current Psychiatry, CNS
Spectrums and Postgraduate Medicine.
Dr. Mattingly has dedicated the past 25 years of his career to caring for children, adolescents and adults with ADHD and associated conditions. His work on medical education in ADHD received the “Best Poster Award” at this year’s ADHD World Congress in Vancouver. Most importantly, as a parent of a child with developmental disabilities, Dr. Mattingly understands the ongoing need for improved coordination of research, education and clinical care for our patients and their families.

Brooke Molina, Ph.D., is Professor of Psychiatry, Psychology, Pediatrics & Translational Science at the University of Pittsburgh School of Medicine where she directs the activities of the Youth and Family Research Program (aka ADHD Research Program). She conducts research on the course, causes, and treatments of ADHD and substance abuse. Her studies, federally funded since 1995, include single and multi-site longitudinal studies of children with and without ADHD followed into adulthood, studies of pharmacologic and behavioral treatments, investigation of the neurobiological underpinnings of these disorders, and provision of ADHD-related care (especially prevention of stimulant misuse) in primary care. She serves on the editorial boards of several scientific journals, served as a member of the CHADD professional advisory board, reviews grant applications for the National Institutes of Health and served a two-year term as study section chair. She is the Co-Director of the Developmental Alcohol Research Training program (T32) Institutional National Research Service Award at the University of Pittsburgh.

Andrew A. Nierenberg, M.D. holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Massachusetts General Hospital (MGH) and is the Director of the Dauten Family Center for Bipolar Treatment Innovation, Associate Director of the Depression Clinical and Research Program, and Director of Training and Education for the MGH Research Institute. Dr. Nierenberg’s academic appointment is Professor of Psychiatry at Harvard Medical School. He has published over 430 papers and has been listed among the Best Doctors in North America for the treatment of mood and anxiety disorders continuously since 1994. He has received the National Depression and Manic Depression Association (NDMDA) and Depression Bipolar Support Alliance Gerald L. Klerman Young Investigator and Senior Investigator Awards. Additionally, Dr. Nierenberg has been awarded the Brain and Behavior Research Foundation Colvin Prize for outstanding achievement in mood disorders research, and was listed among the World’s Most Influential Scientific Minds 2014 and 2015 by Thompson Reuters for being in the top 1% of literature citations in psychiatry or psychology worldwide. In his spare time, Dr. Nierenberg is an avid cyclist and a struggling tenor saxophone player.

Joel Nigg, Ph.D., is a Professor of Psychiatry and Behavioral Neuroscience and Director of the Center for ADHD Research at Oregon Health & Science University in Portland Oregon. He obtained his AB at Harvard College, MSW at The University of Michigan, and PhD in Clinical Psychology at the University of California at Berkeley. He is a licensed clinical psychologist with clinical experience in multiple settings. He is a leading researcher in the area of developmental psychopathology with a focus on ADHD. He and his teams have published some 200 peer reviewed scientific papers in addition to numerous chapters, editorials, and commentaries; his work has been cited nearly 20,000 times in the literature. He is the author of 2 books on ADHD. His work has been funded continuously by NIMH for over 20 years. The recipient of several awards, he has served on the editorial boards of several leading scientific journals.

Anthony L. Rostain, M.D., M.A. is Professor of Psychiatry and Pediatrics at the Perelman School of Medicine of the University of Pennsylvania. He is Director of Education for the Department of Psychiatry where he is responsible for overseeing medical student education, residency and fellowship training. He is triple boarded in pediatrics, adult psychiatry, and child and adolescent psychiatry. His primary clinical focus is "lifespan neurodevelopmental psychiatry," treating patients of all ages with Attention-Deficit / Hyperactivity Disorder, Autistic Spectrum Disorders (including Asperger Syndrome / High Functioning Autism), Tourette Syndrome, Learning Disabilities (Verbal and Nonverbal) and social communication disorders. He is an attending and supervising psychiatrist at The Children's Hospital of Philadelphia (CHOP) and University of Pennsylvania Health System (UPHS).

Dr. Rostain is the Director of the Adult Development Disorders Unit (Penn Behavioral Health) which includes the Adult ADHD Treatment and Research Program and the Adult Social Learning Disorders Program. He is also Director of The Children's Hospital of Philadelphia Behavioral Health Center’s Developmental Neuropsychiatry Program. Dr. Rostain is also a faculty member in the Center for Neuroscience and Society where he participates in research seminars and teaches about clinical applications and ethical aspects of cognitive neuroscience. Most recently, he has been active in addressing the growing trend toward nonmedical use of stimulants for cognitive enhancement.

Dr. Rostain's research interests have focused on improving clinical outcomes for patients with ADHD and other neuropsychiatric disorders, and in creating effective service systems for high risk children, youth and families. He completed a study of combined medication and cognitive-behavioral therapy (CBT) for adults with ADHD which served as the basis of a textbook on this topic. He is currently involved in studies of differential therapeutic efficacy of medication and CBT, of developmental processes in young adults with ADHD, of predictors of treatment response for patients with co-morbid conditions such as anxiety and substance abuse.

Dr. Rostain holds several leadership positions in national professional organizations. He is President of the American Professional Society of ADHD and Related Disorders (APSARD), is a National Board member of Children and Adults with ADHD (CHADD), and is on the Executive Council of the American Association of Directors of Psychiatry Residency Training (AADPRT) for which he chairs the Model Curriculum Committee. He also recently completed teaching a seminar on Coursera.org called “Pay Attention: ADHD Through the Lifespan.”

Dr. Solanto is Professor of Pediatrics and Psychiatry at the Hofstra-Northwell School of Medicine. She completed her undergraduate education at Princeton University, and received her Ph.D. in Clinical Psychology from the University at Buffalo. She subsequently completed an NIMH post-doctoral fellowship in the Department of Psychiatry at the Albert Einstein College of Medicine. Prior to joining Hofstra, she was Director of the ADHD Center in the Department of Psychiatry at the Mount Sinai School of Medicine, and an Associate Professor at NYU School of Medicine.

Dr. Solanto’s research on the cognitive and behavioral functioning of children with ADHD, the effects of psychostimulants, and characteristics of the subtypes of ADHD has been supported by grants from the National Institute of Neurological Diseases, the
National Institute of Mental Health, and the National Institute of Child Health and Human Development. Dr. Solanto has also worked extensively with adults with ADHD. She developed a novel cognitive-behavioral intervention which targets problems of time-management and organization in adults with ADHD and which was the focus of an NIMH-sponsored treatment efficacy study, published in the American Journal of Psychiatry. The manual for therapists, titled Cognitive-Behavioral Treatment of Adult ADHD: Targeting Executive Dysfunction was published in 2011 (Guilford Press).

Dr. Solanto is active in clinical work with adults and children, and in the training of psychiatrists and psychologists to diagnose and treat AD/HD and related disorders. She has conducted workshops with parents concerning identification and treatment of children with AD/HD, and has presented to adult self-help organizations on strategies to improve organization and self-management. Dr. Solanto has published numerous scholarly papers concerning ADHD in children and adults and is a frequent reviewer for professional journals. She has served as a grant reviewer for NIMH. Currently, she is a member of the editorial boards of the Journal of Attention Disorders and The ADHD Report. She serves on the professional advisory boards of CHADD (Children and Adults with ADHD) and NCLD (National Center for Learning Disabilities). Dr. Solanto edited a volume (with Amy Arnsten and Xavier Castellanos) titled: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience, (Oxford University Press), which is an investigation of the mechanisms of action of stimulants in ADHD.

Mark Stein, PhD, is Professor of Psychiatry and Behavioral Sciences, and Pediatrics at The University of Washington, and Director of the Program to Evaluate and Enhance Attention, Regulation, and Learning (PEARL Clinic) at Seattle Children’s Hospital.  An active clinician and researcher, he has specialized in ADHD for over 30 years, and started the Hyperactivity, Attention, and Learning Problems Clinic at The University of Chicago in 1987.  He is a fellow if the American Psychological Association, and a diplomate in clinical psychology (ABPP). In 2013, he completed a MacLean Fellowship in Clinical and Medical Ethics at The University of Chicago.

His clinical work and teaching emphasis is on differential diagnoses and multidisciplinary treatment planning of ADHD throughout the lifespan. He has trained hundreds of pediatricians, psychologists, and psychiatrists who have rotated through the HALP and now the PEARL Clinic, and has evaluated thousands of children, adolescents, and adults.

Dr. Stein has over 100 publications, including articles in Journal of the American Academy of Child and Adolescent Psychiatry, Journal of Child Psychiatry and Psychology, Pediatrics, Nature Medicine, and the New England Journal of Medicine. In 1999, he coedited the text book, Attention Deficit and Hyperactivity in Children and Adults.  Dr. Stein is on the editorial board for Journal of Attention Disorders and Journal of Child and Adolescent Psychopharmacology. Dr. Stein has received research support from the National Institute of Health, the Smart Family Foundation, and industry.

He has done significant work on medical mimics of ADHD, such a sleep problems and thyroid disease, adaptive dysfunction, dose response and comparative efficacy of ADHD medications, and molecular genetics. Along with collaborators, Drs. Jeffrey Newcorn, Andrea Chronis-Tuscano, Margaret Weiss, and Tanya Froehlich, current work is on treating ADHD in parents, novel treatments, sleep, and personalizing ADHD treatment.

Dr. Stein is a former member of the CHADD National Advisory Board and research editor of Attention magazine. HE has been a board member of APSARD since its founding, and has been on the executive committee for three years, and co-director of the annual meeting for the past 2 years.

Dr. Craig B.H. Surman is the Scientific Coordinator of the Adult ADHD Research Program at Massachusetts General Hospital, an Assistant Professor of Psychiatry at Harvard Medical School, and a member of the CHADD Professional Advisory Board. Dr. Surman’s research strives to improve self-regulation challenges in adulthood. He co-authored two books, “ADHD in Adults: A Practical Guide to Evaluation and Management”, and “FAST MINDS: How To Thrive If You Have ADHD (or think you might).”

Roberta Waite, EdD, PMHCNS-BC, FAAN, ANEF is a Professor and serves as the Associate Dean of Community-Centered Health and Wellness and Academic Integration at Drexel University College of Nursing and Health Professions (CNHP). She also holds a secondary appointment in the Health Sciences and Services Research Department at CNHP and serves as the Executive Director of the Stephen and Sandra Sheller 11th St Family Health Services, a FQHC certified as a Level III NCQA patient-centered medical home. She is a graduate of Widener University (BSN) and the University of Pennsylvania (MSN). She earned a Doctorate in Higher Education Administration-Leadership from Widener University and completed a 2-year post-doctoral research fellowship (T32) at the Center for Health Disparities Research at the University of Pennsylvania, School of Nursing. Dr. Waite is also a Josiah Macy Faculty Scholar Alumni. Dr Waite’s educational research focuses on leadership development of students in the health professions while concurrently fostering critical consciousness using a social justice lens. Her clinical scholarly work looks at social determinants of health using a life course development perspective, examining depression, adult ADHD, and psychological trauma and adversity. Her research aims to support development of prevention and early intervention measures.

Currently, Dr. Waite serves as a Board of Director for Corporate Trinity Health, which serves people in 21 states with 82 hospitals; 89 continuing care facilities, home health, and hospice programs. She is also on several editorial boards for nursing and interdisciplinary journals.